A Phase 2 Trial of Tandutinib in Combination With Bevacizumab for Patients With Recurrent High-Grade Gliomas.
Phase of Trial: Phase II
Latest Information Update: 07 Nov 2015
At a glance
- Drugs Tandutinib (Primary) ; Bevacizumab
- Indications Anaplastic astrocytoma; Astrocytoma; Glioblastoma; Glioma; Gliosarcoma; Oligodendroglioma
- Focus Therapeutic Use
- 09 Aug 2011 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
- 09 Aug 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 27 Aug 2010 Planned end date changed from 1 Jan 2009 to 1 Aug 2011 as reported by ClinicalTrials.gov.